Skip to main content
Article thumbnail
Location of Repository

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients

By Evgeny N Suspitsin, Nathalia Yu Sherina, Daria N Ponomariova, Anna P Sokolenko, Aglaya G Iyevleva, Tatyana V Gorodnova, Olga A Zaitseva, Olga S Yatsuk, Alexandr V Togo, Nathalia N Tkachenko, Grigory A Shiyanov, Oksana S Lobeiko, Nadezhda Yu Krylova, Dmitry E Matsko, Sergey Ya Maximov, Adel F Urmancheyeva, Nathalia V Porhanova and Evgeny N Imyanitov
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2664323
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1997). 30% of early-onset breast cancer patients among Ashkenazi women.
    2. (2004). A: One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.
    3. (1996). Barkardottir RB: High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res
    4. (1998). BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
    5. (2005). Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat
    6. (2002). breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Lett
    7. (2003). BY: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer
    8. (2006). CHEK2 variants predispose to benign, borderline and lowgrade invasive ovarian tumors. Gynecol Oncol
    9. contribute only to a limited fraction of breast cancer cases in Russia.
    10. Eds: Cancer principles and practice in oncology eighth edition. Lippincott Williams and Wilkins;
    11. (1999). Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet
    12. (2001). Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families. Clin Genet
    13. (1997). Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet
    14. (2004). Gallion HH: Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol
    15. (2003). Hereditary ovarian cancer in Poland.
    16. (2001). HH: BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study. Gynecol Oncol
    17. (2008). High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol
    18. (2000). Hoskins WJ: Clinicopathologic features of BRCAlinked and sporadic ovarian cancer. JAMA
    19. (2006). IG: Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res
    20. (2006). Imyanitov EN: CHEK2 1100delC mutation is frequent among Russian breast cancer patients. Breast Cancer Res Treat
    21. (2007). Imyanitov EN: Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer
    22. (2008). Imyanitov EN: Ovarian cancer patient with germ-line mutation
    23. (2008). Is it time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
    24. (2007). Kenter GG: Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort. Genet Med
    25. (1997). Levy-Lahad E: High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol
    26. (2003). Modan B: Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol Oncol
    27. (1995). Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum Mol Genet
    28. (1995). Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res
    29. (2005). Mutational analysis of the BRCA1 gene in 30 Czech ovarian cancer patients.
    30. (2000). mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Gynecol Oncol
    31. (1996). Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res
    32. (2002). Narod SA: Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.
    33. (2002). National Israeli Study of Ovarian Cancer: Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.
    34. (2001). Nevanlinna H: BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
    35. (2002). Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumours. Ann Hum Genet
    36. (2002). Offit K: Ovarian cancer risk
    37. (2000). Olah E: Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
    38. (2007). Olopade OI: Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer
    39. (2001). Ovarian cancer survival
    40. (2002). Ozcelik H: BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Hum Mutat
    41. (2005). R: BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer
    42. (2001). SA: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    43. (2008). Sadetzki S: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    44. (2004). Sperling K: Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland.
    45. (2005). Stengrevics A: High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia. Fam Cancer
    46. (1999). Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.
    47. (2008). Villems R: Two sources of the Russian patrilineal heritage in their Eurasian context.
    48. (2000). with ovarian cancer.
    49. (1999). Zeillinger R: BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization. Clin Chem
    50. (2000). Ziogas A: Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.